U.S. stocks were higher, with the Dow Jones index gaining more than 400 points on Monday.
On Friday, the FDA approved BridgeBio Pharma's Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. Also, HC Wainwright maintained a Buy rating on the stock and raised its price target from $43 to $49.
BridgeBio Pharma shares jumped 22.3% to $28.64 on Monday.
Here are some other big stocks recording gains in today's session.
Now Read This:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
